

CLAIMS

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims

1-23. (Cancelled)

24. (Currently Amended) A method of treatment of or protection against an inflammatory disease ~~wherein the disease is Th1-mediated~~, comprising administering an effective amount of a peptide of 7-30 amino acids ~~having the sequence of a part of the amino acid sequence of a mycobacterial protein having a conserved mammalian stress protein homologue, said part comprising at least 5 amino acids which are identical with the corresponding amino acids in the same relative position in one of derived from the sequence sequences 81-100 and 241-270 of SEQ ID NO. 1 representing the sequence of the stress protein hsp65 of *Mycobacterium tuberculosis*, wherein at least a portion of the peptide comprises a sequence selected from the group consisting of PLXIIAE, LXIIAED, XIIAEDV, II AEDVX, IAEDVXG, AEDVXGE, DVXGEAL, VXGEALS, XGEALST, GEALSTL, EALSTLV, ALSTLVV, LSTLVXN and STLVXNX, and wherein X is any amino acid at least 4 consecutive amino acids of said at least 5 amino acids being identical with the corresponding mammalian stress protein amino acids.~~

25-27. (Cancelled)

28. (Currently Amended) The method of claim ~~2624~~, wherein the peptide comprises ~~at least 5 amino acids which are identical with the corresponding amino acids in the same relative position in one of the sequences the amino acids derived from the sequence 84-95 and 256-265 of SEQ ID NO. 1, wherein the portion of the peptide has the sequence selected from the group consisting of EALSTLV, ALSTLVV, LSTLVXN and STLVXNX.~~

29. (Currently Amended) The method of claim 24, wherein one or more of the amino acids residues has been exchanged with a residue of an amino acid having similar size, charge and polarity, ~~or with amino acid mimetics resulting in one or more backbone modifications.~~

30. (Cancelled)

31. (Previously Presented) The method of claim 24, wherein the peptide is administered parenterally, orally or nasally.

32. (Previously Presented) The method of claim 31, wherein the peptide is administered nasally.

33. (New) The method of claim 25, wherein the peptide is administered parenterally, orally or nasally.

34. (New) The method of claim 28, wherein the portion of the peptide has the sequence selected from the group consisting of EALSTLV, ALSTLVV, LSTLVVN and STLVVNK.

35. (New) The method of claim 28, wherein the portion of the peptide has the sequence selected from the group consisting of EALSTLV, ALSTLVV, LSTLVLN and STLVLNKR.